An interventional study of Bone marrow collection and Blood collection in Trauma Injury, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by University of Florida · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Accidental Injuries with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Accidental Injuries · United States.
Among the 58 studies in Accidental Injuries with a site in United States, this one is the 7th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2014, is one of 26 with no phase, reaches primary completion later than 3 of the 18 other live ones, and was the 6th registered.
128 studies on the registry are indexed under Accidental Injuries; 39 are open to participants now.
Browse Accidental Injuries studies →17 of the 58 studies in Accidental Injuries with a site in United States are open now. Recruiting first, the newest first:
The Metis Foundation · Sites in United States
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Boston Medical Center · Sites in United States
Ages 18+
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Accidental Injuries studies recruiting now, 11 (46%) set no upper age limit and 6 (25%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 110 across 67 interventional studies indexed under Accidental Injuries.
Median enrollment 72 across the 37 interventional studies, 124 across the 21 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 58 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 5 studies filed under Accidental Injuries — fewer than ten, so there is no comparison to draw.
10 of the studies in Accidental Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527599University of Wisconsin, MadisonScreening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention | 2026-12 |
| NCT06812247Boston Medical CenterTherapy Dog Visits for Patients Hospitalized With Traumatic Injuries | 2026-12 |
| NCT02577731University of FloridaHematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury | 2026-12-28 |
| NCT05794165Bryan CottonAntithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism | 2027-04 |
| NCT06793644Dartmouth-Hitchcock Medical CenterStudy of ICG Fluorescence Imaging in Open Fracture and Infection Patients | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 58 studies in Accidental Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Traumatic injury is a leading cause of morbidity and mortality in young adults, and remains a substantial economic and health care burden. Despite decades of promising preclinical and clinical investigations in trauma, investigators understanding of these entities is still incomplete, and few therapies have shown success. During severe trauma, bone marrow granulocyte stores are rapidly released into the peripheral circulation. This release subsequently induces the expansion and repopulation of empty or evacuated space by hematopoietic stem cells (HSCs). Although the patient experiences an early loss of bone marrow myeloid-derived cells, stem cell expansion is largely skewed towards the repopulation of the myeloid lineage/compartment. The hypothesis is that this 'emergency myelopoiesis' is critical for the survival of the severely traumatized and further, failure of the emergency myelopoietic response is associated with global immunosuppression and susceptibility to secondary infection. Also, identifying the release of myeloid derived suppressor cells (MDSCs) in the circulation of human severe trauma subjects. This process is driven by HSCs in the bone marrow of trauma subjects. Additionally, MDSCs may have a profound effect on the nutritional status of the host. The appearance of these MDSCs after trauma is associated with a loss of muscle tissue in these subjects. This muscle loss and possible increased catabolism have huge effects on long term outcomes for these subjects. It is the investigator's goal to understand the differences that occur in these in HSCs and muscle cells as opposed to non-injured and non-infected controls. This work will lead to a better understanding of the myelopoietic and catabolic response following trauma.
This is a prospective study to understand how trauma injuries changes the hematopoeitic stem cells (HSCs) in the bone marrow and muscle cells after trauma injury in elderly subjects is different when compared to non-injured subjects.
There will be three groups for this study: 1) Elective hip surgery subjects, 2) Trauma subjects and 3) deidentified bone marrow of healthy controls.
Samples of bone marrow and a blood sample will be collected at the time of surgery. The deidentified bone marrow of healthy controls will come from a tissue bank.
The blood will be used to perform PB colony assays, ELISAs to test for the following parameters: EPO, G-CSF, Reticulocyte, iron levels and cytokines and inflammatory markers.
The bone marrow and blood samples will be processed and sorted to isolate hematopoeitic stem cells for genomic content to determine genomic expression, oxidative stress, mitochondrial activity, apoptosis, autophagy, analysis of circulating erythroid progenitor cells, reticulocytes, granulocyte-colony stimulating factor assays, erythropoietin and iron levels.
Clinical data and hemodynamic measurements will be collected daily while subjects are hospitalized and trauma surgery subjects will be followed to evaluate for malunion and subsequent additional surgical procedures for repair.
Severe Trauma Population
Inclusion criteria will be:
Blunt and/or penetrating trauma patient with either:
All adults (age 55 and older) require:
Exclusion Criteria will be:
Elective Hip Repair Population
Inclusion criteria will be:
Exclusion Criteria will be:
7. Patients with End Stage Renal Disease 8. Patients with any pre-existing hematological disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bone marrow collection. Blood collection. Clinical data collection.
Other: Bone marrow collection · Other: Blood collection · Other: Clinical data collection
Bone marrow collection. Blood collection. Clinical data collection.
Other: Bone marrow collection · Other: Blood collection · Other: Clinical data collection
Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
Other: Bone marrow collection
Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
Analyze the genomics response of hematopoietic cells between the groups
Through negative isolation columns and flow sorting to isolate the hematopoietic stem cells (HSCs) from a sample for appropriate analysis. The sample will then be enriched using a lineage depletion column which will remove all mature hematopoietic cells. The HSCs will be phenotyped and sorted as CD34+ CD38- Thy1+ CD45RA-. HSCs will be lysed and the RNA genomic content will be isolated. The genomic content will then be processed onto a GeneChip® microarray to analyze the genomic expression.
Time frame: Baseline
Analyze the muscle dysfunction between the groups for oxidative stress
Time frame: Baseline
Analyze the muscle dysfunction between the groups for mitochondrial activity
Time frame: Baseline
Analyze the muscle dysfunction between the groups for apoptosis
Time frame: Baseline
Analyze the muscle dysfunction between the groups for autophagy
Time frame: Baseline
The pathophysiology of injury-associated persistent anemia through PB colony assays of blood.
Time frame: Baseline
The pathophysiology of injury-associated persistent anemia through ELISA test of blood.
Time frame: Baseline
Analyze the genomics response of hematopoietic cells between the groups at additional follow-up surgery
Through negative isolation columns and flow sorting to isolate the hematopoietic stem cells (HSCs) from a sample for appropriate analysis. The sample will then be enriched using a lineage depletion column which will remove all mature hematopoietic cells. The HSCs will be phenotyped and sorted as CD34+ CD38- Thy1+ CD45RA-. HSCs will be lysed and the RNA genomic content will be isolated. The genomic content will then be processed onto a GeneChip® microarray to analyze the genomic expression.
Time frame: Approximately 8 months
Analyze the muscle dysfunction between the groups at additional follow-up surgery for oxidative stress
Time frame: Approximately 8 months
Analyze the muscle dysfunction between the groups at additional follow-up surgery for mitochondrial activity
Time frame: Approximately 8 months
Analyze the muscle dysfunction between the groups at additional follow-up surgery for apoptosis
Time frame: Approximately 8 months
Analyze the muscle dysfunction between the groups at additional follow-up surgery for autophagy
Time frame: Approximately 8 months
Started Jan 2014 (actual). Primary completion is estimated for Dec 2026, 155 months after the start.
Of 34 non-industry interventional studies with no phase under Accidental Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 51. This study's planned 155 months is above that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 7 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.